August 27, 2021

Angela Drysdale
Vice President,
RA
Abbott Diagnostics Scarborough,
Inc. 10 Southgate Road
Scarborough, ME 04074

Device:	ID NOW COVID-19
EUA Number:	EUA200074
Company:	Abbott Diagnostics Scarborough, Inc.
Indication:	Qualitative detection of nucleic acid from the SARS-CoV-2 virus in direct anterior nasal (nasal), nasopharyngeal or throat swabs from individuals who are suspected of COVID-19 by their healthcare provider within the first seven days of the onset of symptoms. Emergency use of this test is limited to authorized laboratories.
Authorized Laboratories:	Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform high, moderate, or waived complexity tests. This test is also authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

REVOKED

Dear Ms. Drysdale:

On March 27, 2020, based on your[1] request, the Food and Drug Administration (FDA) issued a letter authorizing the emergency use of your product[2] for the qualitative detection of nucleic acid from the SARS-CoV-2 virus in direct nasal, nasopharyngeal or throat swabs from individuals who are suspected of COVID-19 by their healthcare provider within the first seven days of the onset of symptoms, pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. §360bbb-3). Based on your requests, FDA granted updates

[1] For ease of reference, this letter will use the term "you" and related terms to refer to the Abbott Diagnostics Scarborough, Inc.
[2] For ease of reference, this letter will use the term "your product" to refer to the ID NOW COVID-19 used for the indication identified above.

to the authorized labeling on April 21, 2020[3] as well as revised and reissued the letter on June 1, 2020[4] and September 17, 2020.[5]

On May 23, 2021, you requested to further revise your Emergency Use Authorization (EUA). Based on that request, and having concluded that revising the September 17, 2020, EUA is appropriate to protect the public health or safety under section 564(g)(2)(C) of the Act, FDA is reissuing the September 17, 2020 letter in its entirety with the revisions incorporated.[6] Accordingly, your product is hereby authorized pursuant to section 564 of the Act when used pursuant to the Scope of Authorization (Section II) and Conditions of Authorization (Section IV) of this reissued letter.

On February 4, 2020, pursuant to Section 564(b)(1)(C) of the Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes COVID-19. Pursuant to Section 564 of the Act, and on the basis of such determination, the Secretary of HHS then declared that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19 subject to the terms of any authorization issued under Section 564(a) of the Act.[7]

FDA considered the totality of scientific information available in authorizing the emergency

REVOKED

[3] On April 21, 2020, your request was granted to update the Instructions for Use (IFU or Package Insert) of your product to remove nasal, nasopharyngeal, or throat swabs eluted in viral transport media swabs in VTM as a specimen type, due to concerns that the dilution will result in decreased detection of low positive samples that are near the limit of detection of your product.

[4] On June 1, 2020, the revisions to the March 27, 2020 letter included: (1) revised intended use to indicate that negative results should be treated as presumptive and if inconsistent with clinical signs and symptoms or necessary for patient management should be tested with different authorized or cleared molecular tests; (2) revised intended use to clarify that your product is also authorized for use at POC, i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation; (3) updated the labeling to improve specimen handling procedures and include limitations and information about risks concerning negative results; (4) updated the healthcare provider and patient fact sheets to reflect consistency with more recent authorizations; and (5) incorporated changes consistent with the April 21, 2020, granting letter.

[5] On September 17, 2020, the revisions to the June 1, 2020 letter included: (1) revised intended use to indicate that testing is for specimens collected "from individuals who are suspected of COVID-19 by their healthcare provider within the first seven days of the onset of symptoms," (2) revised intended use to clarify that testing is authorized for laboratories certified under CLIA and meet the requirements to perform high, moderate, or waived complexity tests; (3) revised intended use to clarify that testing facilities within the United States and its territories are required to report all results to the appropriate public health authorities; (4) revised the labeling to update specimen transport and storage recommendations; (5) revised the labeling to include results of the FDA SARS-CoV-2 Reference Panel Testing; (6) updated conditions of authorization to reflect consistency with more recent authorizations; and, (7) revised the healthcare provider and patient fact sheets to reflect the intended use updates and language more consistent with recent authorizations.

[6] The revisions to the September 17, 2020 letter and authorized labeling include: (1) extension of the kit stability claim from 6-months to 9-months, (2) updates to the *in silico* inclusivity analysis study results, (3) updates to the healthcare provider and patient fact sheets as well as the conditions of authorization to reflect language used in more recent authorizations, and (4) addition of Conditions R. and S. to evaluate device performance with viral mutations.

[7] U.S. Department of Health and Human Services, *Determination of a Public Health Emergency and Declaration that Circumstances Exist Justifying Authorizations Pursuant to Section 564(b) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3*. 85 FR 7316 (February 7, 2020).

use of your product for the indication above. A summary of the performance information FDA relied upon is contained in the Package Insert (identified below).

Having concluded that the criteria for issuance of this authorization under Section 564(c) of the Act are met, I am authorizing the emergency use of your product, described in the Scope of Authorization of this letter (Section II), subject to the terms of this authorization.

I. Criteria for Issuance of Authorization

I have concluded that the emergency use of your product meets the criteria for issuance of an authorization under Section 564(c) of the Act, because I have concluded that:

1. The SARS-CoV-2 can cause a serious or life-threatening disease or condition, including severe respiratory illness, to humans infected by this virus;

2. Based on the totality of scientific evidence available to FDA, it is reasonable to believe that your product may be effective in diagnosing COVID-19, and that the known and potential benefits of your product when used for diagnosing COVID-19, outweigh the known and potential risks of your product; and

3. There is no adequate, approved, and available alternative to the emergency use of your product.[8]

II. Scope of Authorization

I have concluded, pursuant to Section 564(d)(1) of the Act, that the scope of this authorization is limited to the indication above.

Authorized Product Details

Your product is for the qualitative detection of nucleic acid from the SARS-CoV-2 virus in direct anterior nasal (nasal), nasopharyngeal or throat swabs from individuals who are suspected of COVID-19 by their healthcare provider within the first seven days of the onset of symptoms. The SARS- CoV-2 nucleic acid is generally detectable in respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 nucleic acid; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Negative results should be treated as presumptive and, if inconsistent with clinical signs and symptoms or necessary for patient management, should be tested with different authorized or cleared molecular tests.

Testing of direct nasal, nasopharyngeal or throat swabs from individuals using your product run on the ID NOW Instrument, as outlined in the "ID NOW COVID-19" Package Insert and

[8] No other criteria of issuance have been prescribed by regulation under Section 564(c)(4) of the Act.

REVOKED

"ID NOW COVID-19 Quick Reference Guide," is authorized to be used in laboratories certified under CLIA that meet the requirements to perform high, moderate, or waived complexity tests. This test is authorized for use at the POC, i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation using the ID NOW Instrument outside of the clinical laboratory environment.

Your product is an automated assay that utilizes isothermal nucleic acid amplification technology for the qualitative detection of SARS-CoV-2 viral nucleic acids. It is comprised of a Sample Receiver, containing elution/lysis buffer, a Test Base, comprising two sealed reaction tubes, each containing a lyophilized pellet, a Transfer Cartridge for transfer of the eluted sample to the Test Base, and the ID NOW Instrument. The Sample Receiver and Test Base are inserted into the ID NOW Instrument and the sample added to the Sample Receiver where it is transferred via the Transfer Cartridge to the Test Base, initiating target amplification. Heating, mixing and detection are provided by the ID NOW Instrument. The ID NOW COVID-19 assay includes the following materials or other authorized materials: Test Bases, Sample Receivers, Transfer Cartridges, Patient swabs, Positive Control swab, Negative Control swab.

Your product also includes in the Test Base the following control material, or other authorized control materials (as may be requested under Condition N below), that are processed along with the patient samples when tested with your product. The control listed below must generate expected results in order for a test to be considered valid, as outlined in the Package Insert:

- Internal Control - designed to control for sample inhibition and assay reagent function.

Your product also comes with external positive and negative control swabs, or other authorized control materials (as may be requested under Condition K below), to be run as outlined in the Package Insert, described below.

The above described product, is authorized to be accompanied with labeling entitled "ID NOW COVID-19" Package Insert and "ID NOW COVID-19 Quick Reference Guide" (available at https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use- authorizations-medical-devices/in-vitro-diagnostics-euas), and the following product-specific information pertaining to the emergency use, which is required to be made available to healthcare providers and patients:

- Fact Sheet for Healthcare Providers: Abbott Diagnostics Scarborough, Inc. - ID NOW COVID-19
- Fact Sheet for Patients: Abbott Diagnostics Scarborough, Inc. - ID NOW COVID-19

The above described product, when accompanied by the "ID NOW COVID-19" Package Insert and the "ID NOW COVID-19 Quick Reference Guide" (identified above) and the two Fact Sheets (collectively referenced as "authorized labeling") is authorized to be distributed to and used by authorized laboratories under this EUA, despite the fact that it does not meet certain requirements otherwise required by applicable federal law.

REVOKED

I have concluded, pursuant to Section 564(d)(2) of the Act, that it is reasonable to believe that the known and potential benefits of your product, when used consistent with the Scope of Authorization of this letter (Section II), outweigh the known and potential risks of your product.

I have concluded, pursuant to Section 564(d)(3) of the Act, based on the totality of scientific evidence available to FDA, that it is reasonable to believe that your product may be effective in diagnosing COVID-19, when used consistent with the Scope of Authorization of this letter (Section II), pursuant to Section 564(c)(2)(A) of the Act.

FDA has reviewed the scientific information available to FDA, including the information supporting the conclusions described in Section I above, and concludes that your product (as described in the Scope of Authorization of this letter (Section II)) meets the criteria set forth in Section 564(c) of the Act concerning safety and potential effectiveness.

The emergency use of your product under this EUA must be consistent with, and may not exceed, the terms of this letter, including the Scope of Authorization (Section II) and the Conditions of Authorization (Section IV). Subject to the terms of this EUA and under the circumstances set forth in the Secretary of HHS's determination under Section 564(b)(1)(C) of the Act described above and the Secretary of HHS's corresponding declaration under Section 564(b)(1) of the Act, your product is authorized for the indication above.

REVOKED

III. Waiver of Certain Requirements

I am waiving the following requirements for your product during the duration of this EUA:

- Current good manufacturing practice requirements, including the quality system requirements under 21 CFR Part 820 with respect to the design, manufacture, packaging, labeling, storage, and distribution of your product, but excluding Subpart H (Acceptance Activities, 21 CFR 820.80 and 21 CFR 820.86), Subpart I (Nonconforming Product, 21 CFR 820.90), and Subpart O (Statistical Techniques, 21 CFR 820.250).

IV. Conditions of Authorization

Pursuant to Section 564(e) of the Act, I am establishing the following conditions on this authorization:

Abbott Diagnostics Scarborough, Inc. (You) and Authorized Distributor(s)[9]

A. Your product must comply with the following labeling requirements pursuant to FDA regulations: the intended use statement (21 CFR 809.10(a)(2), (b)(2)); adequate

[9] "Authorized Distributor(s)" are identified by you, Abbott Diagnostics Scarborough, Inc., in your EUA submission as an entity allowed to distribute your device.

directions for use (21 U.S.C. 352(f)), (21 CFR 809.10(b)(5), (7), and (8)); appropriate limitations on the use of the device including information required under 21 CFR 809.10(a)(4); and any available information regarding performance of the device, including requirements under 21 CFR 809.10(b)(12).

B. You and authorized distributor(s) must make your product available with the authorized labeling to authorized laboratories.

C. You and authorized distributor(s) must make available on your website(s) the authorized labeling.

D. You and authorized distributor(s) must include a physical copy of the "ID NOW COVID-19" Package Insert and the "ID NOW COVID-19 Quick Reference Guide" with each shipped product to authorized laboratories.

E. You and authorized distributor(s) must inform authorized laboratories and relevant public health authorities of this EUA, including the terms and conditions herein, and any updates made to your product and authorized labeling.

F. Through a process of inventory control, you and authorized distributor(s) must maintain records of the authorized laboratories to which they distribute the test and number of tests they distribute.

G. You and authorized distributor(s) must collect information on the performance of your product. You will report to FDA any suspected occurrence of false positive and false negative results and significant deviations from the established performance characteristics of the product of which you become aware.

H. You and authorized distributor(s) are authorized to make available additional information relating to the emergency use of your product that is consistent with, and does not exceed, the terms of this letter of authorization.

REVOKED

Abbott Diagnostics Scarborough, Inc. (You)

I. You must notify FDA of any authorized distributor(s) of your product, including the name, address, and phone number of any authorized distributor(s).

J. You must provide authorized distributor(s) with a copy of this EUA and communicate to authorized distributor(s) any subsequent revisions that might be made to this EUA and its authorized accompanying materials (e.g., Fact Sheets).

K. You may request changes to this EUA for your product, including to the Scope of Authorization (Section II in this letter) or to the authorized labeling, including requests to make available additional authorized labeling specific to an authorized distributor. Such additional labeling may use another name for the product but otherwise must be consistent with the authorized labeling, and not exceed the terms of authorization of

this letter. Any request for changes to this EUA should be submitted to the Division of Microbiology (DMD)/Office of Health Technology 7 (OHT7)-Office of In Vitro Diagnostics and Radiological Health (OIR)/Office of Product Evaluation and Quality (OPEQ)/Center for Devices and Radiological Health (CDRH) and require appropriate authorization from FDA prior to implementation.

L. You must comply with the following requirements under FDA regulations: 21 CFR 820 Subpart H (Acceptance Activities, 21 CFR 820.80 and 21 CFR 820.86), Subpart I (Nonconforming Product, 21 CFR 820.90), and Subpart O (Statistical Techniques, 21 CFR 820.250).

M. You must have lot release procedures and the lot release procedures, including the study design and statistical power, must ensure that the tests released for distribution have the clinical and analytical performance claimed in the authorized labeling.

N. If requested by FDA, you must submit lot release procedures to FDA, including sampling protocols, testing protocols, and acceptance criteria that you use to release lots of your product for distribution in the U.S. If such lot release procedures are requested by FDA, you must provide it within 48 hours of the request.

O. You must evaluate the analytical limit of detection and assess traceability[10] of your product with any FDA-recommended reference material(s). After submission to and concurrence with the data by FDA, you will update your labeling to reflect the additional testing. Such labeling updates will be made in consultation with, and require concurrence of, DMD/OHT7-OIR/OPEQ/CDRH.

P. You must further evaluate the clinical performance of your product as agreed with FDA. After submission to and concurrence with the data by, FDA, you will update your labeling to reflect the additional testing. Such labeling updates will be made in consultation with, and require concurrence of, DMD/OHT7-OIR/OPEQ/CDRH.

Q. You must have a process in place to track adverse events, including any occurrence of false results with your product and report to FDA in accordance with 21 CFR Part 803.

R. You must evaluate the impact of SARS-CoV-2 viral mutations on your product's performance. Such evaluations must occur on an ongoing basis and must include any additional data analysis that is requested by FDA in response to any performance concerns you or FDA identify during routine evaluation. Additionally, if requested by FDA, you must submit records of these evaluations for FDA review within 48 hours of the request. If your evaluation identifies viral mutations that affect the stated expected performance of your device, you must notify FDA immediately.

S. If requested by FDA, you must update your labeling within 7 calendar days to

REVOKED

[10] Traceability refers to tracing analytical sensitivity/reactivity back to an FDA-recommended reference material.

include any additional labeling risk mitigations identified by FDA, such as those related to the impact of viral mutations on test performance. Such updates will be made in consultation with, and require concurrence of, DMD/OHT7-OIR/OPEQ/CDRH.

Authorized Laboratories

T. Authorized laboratories using your product must include with test result reports, all authorized Fact Sheets. Under exigent circumstances, other appropriate methods for disseminating these Fact Sheets may be used, which may include mass media.

U. Authorized laboratories using your product will use your product as outlined in the authorized labeling. Deviations from the authorized procedures, including the authorized instruments, authorized extraction methods, authorized clinical specimen types, authorized control materials, authorized other ancillary reagents and authorized materials required to use your product are not permitted.

V. Authorized laboratories that receive your product must notify the relevant public health authorities of their intent to run your product prior to initiating testing.

W. Authorized laboratories using your product must have a process in place for reporting test results to healthcare providers and relevant public health authorities, as appropriate.

X. Authorized laboratories must collect information on the performance of your product and report to DMD/OHT7-OIR/OPEQ/CDRH (via email: CDRH-EUA-Reporting@fda.hhs.gov) and you (via email: ts.scr@abbott.com) any suspected occurrence of false positive or false negative results and significant deviations from the established performance characteristics of your product of which they become aware.

Y. All operators using your product must be appropriately trained in performing and interpreting the results of your product, use appropriate personal protective equipment when handling this kit, and use your product in accordance with the authorized labeling.

Abbott Diagnostics Scarborough, Inc. (You), Authorized Distributors, and Authorized Laboratories

Z. You, authorized distributors, and authorized laboratories using your product must ensure that any records associated with this EUA are maintained until otherwise notified by FDA. Such records will be made available to FDA for inspection upon request.

Conditions Related to Printed Materials, Advertising and Promotion

AA. All descriptive printer matter, advertising and promotional materials, relating to the

REVOKED

use of your product shall be consistent with the authorized labeling, as well as the terms set forth in section 502(a), (q)(1), and (r) of Act, as applicable, and FDA implementing regulations.

BB. No descriptive printed matter, advertising or promotional materials, relating to the use of your product may represent or suggest that this test is safe or effective for the detection of SARS-CoV-2.

CC. All descriptive printed matter, advertising and promotional materials, relating to the use of your product shall clearly and conspicuously state that:

- This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories;
- This product has been authorized only for the detection of nucleic acid from SARS- CoV-2, not for any other viruses or pathogens; and
- The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

The emergency use of your product as described in this letter of authorization must comply with the conditions and all other terms of this authorization.

V. Duration of Authorization

This EUA will be effective until the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 is terminated under Section 564(b)(2) of the Act or the EUA is revoked under Section 564(g) of the Act.

REVOKED

Sincerely,

RADM Denise M. Hinton
Chief Scientist
Food and Drug Administration

Enclosure